Expression of therapeutic proteins after delivery of chemically modified mRNA in mice. - Wikidata - awgldk - TriplyDB

Expression of therapeutic proteins after delivery of chemically modified mRNA in mice.

Expression of therapeutic proteins after delivery of chemically modified mRNA in mice.

http://www.wikidata.org/entity/Q45866149

about

Direct Reprogramming-The Future of Cardiac Regeneration?Recombinant messenger RNA technology and its application in cancer immunotherapy, transcript replacement therapies, pluripotent stem cell induction, and beyond mRNA capping: biological functions and applications The oral and craniofacial relevance of chemically modified RNA therapeutics Therapeutic genome editing: prospects and challenges Tunable protein synthesis by transcript isoforms in human cells Human pluripotent stem cell-derived acinar/ductal organoids generate human pancreas upon orthotopic transplantation and allow disease modelling.mRNA-engineered mesenchymal stem cells for targeted delivery of interleukin-10 to sites of inflammation.Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction Organ-targeted high-throughput in vivo biologics screen identifies materials for RNA delivery.Mesenchymal stem cells engineered to express selectin ligands and IL-10 exert enhanced therapeutic efficacy in murine experimental autoimmune encephalomyelitis.Translation of Angiotensin-Converting Enzyme 2 upon Liver- and Lung-Targeted Delivery of Optimized Chemically Modified mRNA Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo The notorious R.N.A. in the spotlight - drug or target for the treatment of disease N1-methyl-pseudouridine in mRNA enhances translation through eIF2α-dependent and independent mechanisms by increasing ribosome density Understanding RNA modifications: the promises and technological bottlenecks of the 'epitranscriptome'.Characterizing exogenous mRNA delivery, trafficking, cytoplasmic release and RNA-protein correlations at the level of single cells.Neutrophils express distinct RNA receptors in a non-canonical way.Prevention of muscular dystrophy in mice by CRISPR/Cas9-mediated editing of germline DNA Transient delivery of modified mRNA encoding TERT rapidly extends telomeres in human cells.An Enterovirus-Like RNA Construct for Colon Cancer Suicide Gene Therapy.In vivo messenger RNA introduction into the central nervous system using polyplex nanomicelle.Inhibition of Xenograft tumor growth by gold nanoparticle-DNA oligonucleotide conjugates-assisted delivery of BAX mRNA Integration of drug, protein, and gene delivery systems with regenerative medicine.Synthetic chemically modified mRNA (modRNA): toward a new technology platform for cardiovascular biology and medicine.A cationic nanoemulsion for the delivery of next-generation RNA vaccines.Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA.In vitro Study of a Novel Stent Coating Using Modified CD39 Messenger RNA to Potentially Reduce Stent Angioplasty-Associated Complications.mRNA leapfrogs DNA to show promise for therapeutic gene transfer Bioluminescence imaging of stem cell-based therapeutics for vascular regeneration Self-assembled Messenger RNA Nanoparticles (mRNA-NPs) for Efficient Gene Expression.Increased erythropoiesis in mice injected with submicrogram quantities of pseudouridine-containing mRNA encoding erythropoietin.mRNA-Mediated Gene Supplementation of Toll-Like Receptors as Treatment Strategy for Asthma In Vivo.Utilizing native fluorescence imaging, modeling and simulation to examine pharmacokinetics and therapeutic regimen of a novel anticancer prodrug.Correction of Down syndrome and Edwards syndrome aneuploidies in human cell cultures Biomaterials for mRNA delivery.Modified mRNA as an alternative to plasmid DNA (pDNA) for transcript replacement and vaccination therapy.Messenger RNA delivery of a cartilage-anabolic transcription factor as a disease-modifying strategy for osteoarthritis treatment.Gene Therapy: The View from NCATS.Intrathecal delivery of frataxin mRNA encapsulated in lipid nanoparticles to dorsal root ganglia as a potential therapeutic for Friedreich's ataxia.

P2860

Q26800909-FDB89B0E-849C-4B37-A9FC-6F9B43A54FD2 Q26861563-30B5DF08-0810-4A99-BB84-024A2B735CC5 Q27469050-231F5F39-4810-4A23-A24C-AA6EF4872A23 Q28072338-27E1292F-00FE-438E-AFDE-6EA5A8077956 Q28087380-400F78A2-648F-4FDD-9C19-45898B169FE5 Q28603873-CDEC9BA4-6C32-4F23-A563-981A54B183AA Q30313776-B3B33BE0-C5BF-45FC-9998-1002E07EE345 Q30548207-10DC7E91-EA64-4158-A933-C3DD5ED037C1 Q30580723-42D57CED-4A16-4B09-8B3A-984276383D73 Q30624869-B49BEC09-5DEF-4923-B3B1-8F665D7C6151 Q30690412-C1359BB0-AA96-4FD9-99C0-533FEA4E0CFD Q33652543-56A6B457-3370-4C7A-8B2A-507394A77F68 Q33652566-D393AED8-C1A9-4ABE-89A5-108A167F1BEB Q33739733-D04C4DE8-D96F-4657-A73E-AC2DFEEE05EE Q33741117-9DA07473-E7D5-4564-A707-CD73EA62BA3E Q33747514-C0ED9717-7974-4EC7-9BC6-71C607AE97D3 Q33878047-E858BCD1-BF81-4C2C-B31C-1C818FDCA58D Q34244806-98A1A836-A62C-432F-911D-4553276FEEF1 Q34433586-087631B8-552C-4393-9641-462056005695 Q34459333-A2CD1F60-FDD8-4B71-9712-C420C4EB5C68 Q34478571-36383472-EDC8-4331-82C0-84659ADC9124 Q34589906-12C02830-5CBE-4013-8A90-B5E57D5DF75F Q35000872-E2AE0F63-F37B-4F0F-B62F-AA7C78EFCF29 Q35241569-13B4396A-5EC8-4A6B-8C5D-EDF0BF5DB2BD Q35319305-265BFA5E-D97F-41F1-8CFD-7D38D18F27C9 Q35600305-1BD5861F-D59F-4741-A825-5F2BD691475E Q35620919-3FA946A2-3F2F-41BE-98C6-E7A24C72C4C0 Q35779631-79699DEA-D244-4AF5-9B17-EBDE48F0E9A9 Q35876177-AAD85889-13F1-4704-8EFF-197088D7AE04 Q35890008-AA54AE9E-44D8-4A7B-A1C1-0141913E2AE6 Q35909697-C5000F0A-656E-4857-BBD1-441288FD6499 Q35939486-C5938C04-6F76-45A2-A1AE-201AE8D5652B Q35996243-AD1A0BC4-A4E3-4D9E-A1EA-328255E8235A Q36085539-6C102764-3C1B-4927-9011-800E27C3EED2 Q36131210-3CF6A69C-079D-4298-B30F-24965D2AEA69 Q36271488-CF7C03BB-F02C-488D-B48F-8FA4DFFB6035 Q36417403-D4752F2D-015E-4D4E-8F6F-DD48D8DB505A Q36428199-9123DDA9-9773-46CA-BB94-E62F246B1C6D Q36551233-EC43A16C-64B4-4175-93F4-1EB339CF6291 Q36588584-EB732ABD-218D-4F0C-ADDE-3ADAD8E49F63

P2860

Expression of therapeutic proteins after delivery of chemically modified mRNA in mice.

http://www.wikidata.org/entity/Q45866149

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh-hant

name

Expression of therapeutic proteins after delivery of chemically modified mRNA in mice.

@en

Expression of therapeutic proteins after delivery of chemically modified mRNA in mice.

@nl

type

label

Expression of therapeutic proteins after delivery of chemically modified mRNA in mice.

@en

Expression of therapeutic proteins after delivery of chemically modified mRNA in mice.

@nl

prefLabel

Expression of therapeutic proteins after delivery of chemically modified mRNA in mice.

@en

Expression of therapeutic proteins after delivery of chemically modified mRNA in mice.

@nl

P1433

Q45866149-0E986773-E5B1-4E9F-A3CA-48F77F3A64D8

P1476

Q45866149-D79FDB20-E6B5-4D69-B3B3-38F2F6179156

P2093

Q45866149-1CFD9624-E34F-47D7-9F55-490547AC66CA

Q45866149-271CE5DB-9620-4836-9B26-C0A1C9422E55

Q45866149-5390D39B-7FD8-4AFD-9628-D40746F72DBF

Q45866149-53C601D6-50FA-4116-B252-AD121B6DDC82

Q45866149-6728E49D-5F7B-4E9D-A582-BB2B9DF882E3

Q45866149-73AFBD6D-25F0-4C59-BD96-C90512572C85

Q45866149-80278DF0-35AA-40B5-B909-796EB5624052

Q45866149-9C8276E1-8014-4DC3-8358-ECE3097972AC

Q45866149-A574EF6B-A7EA-4509-97AC-10C59E5AF782

Q45866149-A9243FF8-A744-423E-B4CE-2A17EF789678

P2888

Q45866149-8EF14D7F-9630-4882-B98F-EC22F1E388CD

P304

Q45866149-12320F2C-931A-4870-82E4-01214C3CAE30

P31

Q45866149-F27630B1-52F9-423F-AE9C-77A41156101E

P356

Q45866149-B682E93F-37A4-43CA-B86D-02CAC9718B97

P433

Q45866149-4D7B677C-3D93-40C7-8B7B-ADF3DE73AAA3

P478

Q45866149-441E58B2-BC9B-4644-8961-104668C6269E

P577

Q45866149-F93A4D47-4C83-4CC8-812A-9D08611BC9D6

P5875

Q45866149-DC905F1B-4EFA-440F-8056-651EE3C08BB8

P6179

Q45866149-E717858E-9B4C-48D7-94C9-35CC0D7B5E41

P698

Q45866149-F468DB65-37FC-4966-AC66-220531275550

P356

P1433

Nature Biotechnology

P1476

Expression of therapeutic proteins after delivery of chemically modified mRNA in mice.

@en

P2093

Andrea Schams

http://www.w3.org/2001/XMLSchema#string

Andreas W Flemmer

http://www.w3.org/2001/XMLSchema#string

Carsten Rudolph

http://www.w3.org/2001/XMLSchema#string

Dominik Hartl

http://www.w3.org/2001/XMLSchema#string

Gabriela Nica

http://www.w3.org/2001/XMLSchema#string

Günther Hasenpusch

http://www.w3.org/2001/XMLSchema#string

Iris Bittmann

http://www.w3.org/2001/XMLSchema#string

Joseph Rosenecker

http://www.w3.org/2001/XMLSchema#string

Lauren E Mays

http://www.w3.org/2001/XMLSchema#string

Manish K Aneja

http://www.w3.org/2001/XMLSchema#string

P2888

P304

154-157

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NBT.1733

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

29

http://www.w3.org/2001/XMLSchema#string

P577

2011-01-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49739482

http://www.w3.org/2001/XMLSchema#string

P6179

1002080286

http://www.w3.org/2001/XMLSchema#string

P698

21217696

http://www.w3.org/2001/XMLSchema#string